Melinda T Coughlan

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1843155/melinda-t-coughlan-publications-by-year.pdf
Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78 papers	5,189 citations	35 h-index	72 g-index
90 ext. papers	6,081 ext. citations	5.3 avg, IF	5.72 L-index

#	Paper	IF	Citations
78	Reduced Growth, Altered Gut Microbiome and Metabolite Profile, and Increased Chronic Kidney Disease Risk in Young Pigs Consuming a Diet Containing Highly Resistant Protein.. *Frontiers in Nutrition*, **2022**, 9, 816749	6.2	0
77	High-intensity training induces non-stoichiometric changes in the mitochondrial proteome of human skeletal muscle without reorganisation of respiratory chain content. *Nature Communications* , **2021**, 12, 7056	17.4	7
76	Targeted deletion of nicotinamide adenine dinucleotide phosphate oxidase 4 from proximal tubules is dispensable for diabetic kidney disease development. *Nephrology Dialysis Transplantation* , **2021**, 36, 988-997	4.3	3
75	Processed foods drive intestinal barrier permeability and microvascular diseases. *Science Advances*, **2021**, 7,	14.3	27
74	Gut microbiome, prebiotics, intestinal permeability and diabetes complications. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2021**, 35, 101507	6.5	12
73	The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition). *Endocrinology, Diabetes and Metabolism*, **2021**, 4, e00278	2.7	0
72	Renal ACE2 (Angiotensin-Converting Enzyme 2) Expression Is Modulated by Dietary Fiber Intake, Gut Microbiota, and Their Metabolites. *Hypertension*, **2021**, 77, e53-e55	8.5	3
71	SOD2 in skeletal muscle: New insights from an inducible deletion model. *Redox Biology*, **2021**, 47, 102135	11.3	0
70	Intravascular Follistatin gene delivery improves glycemic control in a mouse model of type 2 diabetes. *FASEB Journal*, **2020**, 34, 5697-5714	0.9	3
69	Exploring the role of the metabolite-sensing receptor GPR109a in diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, **2020**, 318, F835-F842	4.3	3
68	Deficiency of Prebiotic Fiber and Insufficient Signaling Through Gut Metabolite-Sensing Receptors Leads to Cardiovascular Disease. *Circulation*, **2020**, 141, 1393-1403	16.7	58
67	The Devil's in the Detail: The Importance of Specific, Descriptive Language for Reproducibility in Nutrition Science. *Journal of Renal Nutrition*, **2020**, 30, 274-275	3	0
66	Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D. *Clinical Science*, **2020**, 134, 239-259	6.5	20
65	Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility. *Diabetes*, **2020**, 69, 83-98	0.9	20
64	Confirmation of the Cardioprotective Effect of MitoGamide in the Diabetic Heart. *Cardiovascular Drugs and Therapy*, **2020**, 34, 823-834	3.9	5
63	Mutation of regulatory phosphorylation sites in PFKFB2 worsens renal fibrosis. *Scientific Reports*, **2020**, 10, 14531	4.9	3
62	The Mitochondria-Targeted Methylglyoxal Sequestering Compound, MitoGamide, Is Cardioprotective in the Diabetic Heart. *Cardiovascular Drugs and Therapy*, **2019**, 33, 669-674	3.9	11

61	Globally elevating the AGE clearance receptor, OST48, does not protect against the development of diabetic kidney disease, despite improving insulin secretion. *Scientific Reports*, **2019**, 9, 13664	4.9	2
60	Dietary Advanced Glycation End Products: Digestion, Metabolism and Modulation of Gut Microbial Ecology. *Nutrients*, **2019**, 11,	6.7	85
59	Modulation of the Gut Microbiota by Resistant Starch as a Treatment of Chronic Kidney Diseases: Evidence of Efficacy and Mechanistic Insights. *Advances in Nutrition*, **2019**, 10, 303-320	10	35
58	Obesity associated advanced glycation end products within the human uterine cavity adversely impact endometrial function and embryo implantation competence. *Human Reproduction*, **2018**, 33, 654-665	5.7	27
57	Methods in renal research: Measurement of autophagic flux in the renal cortex ex vivo. *Nephrology*, **2018**, 23, 815-820	2.2	1
56	RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis. *Diabetes*, **2018**, 67, 960-973	0.9	9
55	Association between habitual dietary and lifestyle behaviours and skin autofluorescence (SAF), a marker of tissue accumulation of advanced glycation endproducts (AGEs), in healthy adults. *European Journal of Nutrition*, **2018**, 57, 2209-2216	5.2	17
54	Use of Readily Accessible Inflammatory Markers to Predict Diabetic Kidney Disease. *Frontiers in Endocrinology*, **2018**, 9, 225	5.7	20
53	Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction. *Islets*, **2018**, 10, 10-24	2	11
52	Increased liver AGEs induce hepatic injury mediated through an OST48 pathway. *Scientific Reports*, **2017**, 7, 12292	4.9	16
51	NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy. *Diabetes*, **2017**, 66, 2691-2703	0.9	88
50	Stirring the Pot: Can Dietary Modification Alleviate the Burden of CKD?. *Nutrients*, **2017**, 9,	6.7	24
49	Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. *Clinical Science*, **2016**, 130, 711-20	6.5	68
48	Mitochondrial Fission/Fusion and Disease **2016**, 1-7		
47	Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial Homeostasis. *Diabetes*, **2016**, 65, 1085-98	0.9	34
46	Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?. *Current Drug Targets*, **2016**, 17, 1252-64	3	8
45	Dietary Advanced Glycation End Products and Risk Factors for Chronic Disease: A Systematic Review of Randomised Controlled Trials. *Nutrients*, **2016**, 8, 125	6.7	107
44	Challenging the dogma of mitochondrial reactive oxygen species overproduction in diabetic kidney disease. *Kidney International*, **2016**, 90, 272-279	9.9	51

43	Effect of diet-derived advanced glycation end products on inflammation. *Nutrition Reviews*, **2015**, 73, 737-59	6.4	85
42	Targeting Mitochondria and Reactive Oxygen Species-Driven Pathogenesis in Diabetic Nephropathy. *Review of Diabetic Studies*, **2015**, 12, 134-56	3.6	58
41	Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: a study protocol for a double-blind placebo-controlled randomised crossover clinical trial. *BMC Endocrine Disorders*, **2014**, 14, 55	3.3	57
40	Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. *Diabetology and Metabolic Syndrome*, **2014**, 6, 86	5.6	24
39	Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy?. *British Journal of Pharmacology*, **2014**, 171, 1917-42	8.6	161
38	Nox-4 deletion reduces oxidative stress and injury by PKC-□associated mechanisms in diabetic nephropathy. *Physiological Reports*, **2014**, 2, e12192	2.6	74
37	Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. *British Journal of Nutrition*, **2014**, 111, 1147-61	3.6	201
36	Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. *Amino Acids*, **2014**, 46, 321-6	3.5	23
35	Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease. *Antioxidants and Redox Signaling*, **2013**, 19, 331-43	8.4	31
34	Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. *Nephrology*, **2013**, 18, 47-56	2.2	26
33	Glucose homeostasis can be differentially modulated by varying individual components of a western diet. *Journal of Nutritional Biochemistry*, **2013**, 24, 1251-7	6.3	18
32	Advanced glycation end products augment experimental hepatic fibrosis. *Journal of Gastroenterology and Hepatology (Australia)*, **2013**, 28, 369-76	4	40
31	Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. *Free Radical Biology and Medicine*, **2012**, 52, 716-723	7.8	91
30	Advanced glycation end products as environmental risk factors for the development of type 1 diabetes. *Current Drug Targets*, **2012**, 13, 526-40	3	17
29	Targeted reduction of advanced glycation improves renal function in obesity. *Kidney International*, **2011**, 80, 190-8	9.9	83
28	Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. *Diabetologia*, **2011**, 54, 1032-42	10.3	36
27	Advanced glycation end products are direct modulators of □cell function. *Diabetes*, **2011**, 60, 2523-32	0.9	111
26	Temporal increases in urinary carboxymethyllysine correlate with albuminuria development in diabetes. *American Journal of Nephrology*, **2011**, 34, 9-17	4.6	11

25	miR-200a Prevents renal fibrogenesis through repression of TGF-β expression. *Diabetes*, **2011**, 60, 280-7	0.9	279
24	Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man. *American Journal of Nephrology*, **2011**, 34, 347-55	4.6	30
23	Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse. *Diabetes*, **2010**, 59, 3198-207	0.9	81
22	Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, **2010**, 298, F763-70	4.3	88
21	Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy. *American Journal of Nephrology*, **2010**, 32, 73-82	4.6	18
20	Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. *Kidney International*, **2010**, 78, 287-95	9.9	58
19	Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. *Journal of Hypertension*, **2010**, 28, 780-8	1.9	64
18	Receptor for AGEs (RAGE) blockade may exert its renoprotective effects in patients with diabetic nephropathy via induction of the angiotensin II type 2 (AT2) receptor. *Diabetologia*, **2010**, 53, 2442-51	10.3	55
17	RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 742-52	12.7	323
16	Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study. *Journal of Vascular Surgery*, **2009**, 50, 626-31	3.5	13
15	Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. *Diabetes*, **2008**, 57, 2461-9	0.9	334
14	Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. *Diabetes*, **2008**, 57, 460-9	0.9	281
13	Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. *American Journal of Physiology - Endocrinology and Metabolism*, **2008**, 295, E323-30	6	83
12	Oxidative stress as a major culprit in kidney disease in diabetes. *Diabetes*, **2008**, 57, 1446-54	0.9	843
11	Oxidative stress and advanced glycation in diabetic nephropathy. *Annals of the New York Academy of Sciences*, **2008**, 1126, 190-3	6.5	46
10	Can you reduce your AGE?: Strategies to prevent AGE accumulation in diabetes. *Drug Discovery Today: Therapeutic Strategies*, **2007**, 4, 85-92		2
9	Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. *Diabetologia*, **2007**, 50, 1770-9	10.3	112
8	Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?. *Endocrinology*, **2007**, 148, 886-95	4.8	99

7	Renal microvascular injury in diabetes: RAGE and redox signaling. *Antioxidants and Redox Signaling*, **2007**, 9, 331-42	8.4	31
6	Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?. *Annals of the New York Academy of Sciences*, **2005**, 1043, 750-8	6.5	5
5	Interactions between renin angiotensin system and advanced glycation in the kidney. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 2976-84	12.7	118
4	Repression of oxidant-induced nuclear factor-kappaB activity mediates placental cytokine responses in gestational diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 3585-94	5.6	48
3	Altered placental oxidative stress status in gestational diabetes mellitus. *Placenta*, **2004**, 25, 78-84	3.4	164
2	Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus. *Diabetic Medicine*, **2001**, 18, 921-7	3.5	79
1	Training-induced bioenergetic improvement in human skeletal muscle is associated with non-stoichiometric changes in the mitochondrial proteome without reorganization of respiratory chain content		4